Sphera Funds Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Sphera Funds Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-512,051	Closed	-$4.28M	–	109
2016 Q1	$4.28M	Buy	512,051 +50,000	+11%	+$410K	0.93%	18
2015 Q4	$4.3M	Sell	462,051 -51,339	-10%	-$512K	0.63%	30
2015 Q3	$5.79M	Hold	513,390	–	–	0.74%	28
2015 Q2	$6.51M	Sell	513,390 -30,000	-6%	-$324K	0.64%	29
2015 Q1	$5.05M	Buy	543,390 +175,000	+48%	+$1.98M	0.53%	42
2014 Q4	$5.28M	Buy	368,390 +150,000	+69%	+$1.77M	0.9%	33
2014 Q3	$2.27M	Buy	218,390 +78,390	+56%	+$1.03M	0.28%	78
2014 Q2	$2.27M	Buy	140,000 +75,000	+115%	+$999K	0.56%	45
2014 Q1	$1.06M	Sell	65,000 -30,000	-32%	-$427K	0.24%	90
2013 Q4	$1.18M	Buy	+95,000	New	+$954K	0.33%	72

Other funds holding VNDA

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sphera Funds Management's VNDA Position: Q2 2016 in Review

Sphera Funds Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2016, closing a stake of 512,051 shares — an estimated $4.28M sold.

Sphera Funds Management first reported a position in VNDA in Q4 2013 and held it in 10 quarters. The position peaked at $6.51M in Q2 2015. 115 funds tracked by Wall St. Rank hold VNDA as of Q2 2016.

Sphera Funds Management reported no remaining Vanda Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Sphera Funds Management sold 512,051 Vanda Pharmaceuticals shares in Q2 2016, an estimated $4.28M.
Sphera Funds Management first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Sphera Funds Management's Vanda Pharmaceuticals position peaked at $6.51M in Q2 2015.
115 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2016.

Based on Sphera Funds Management's 13F filing for Q2 2016, filed 10 Aug 2016.